Jun Wang

Dr. Jun Wang

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2022 in Psychiatry Research
Verified
Journal Article
Closed access
ABAncha Baranova
Ancha Baranova
JWJun Wang
Jun Wang
Hongbao CaoHongbao Cao
Hongbao Cao
JCJian-Huan Chen
Jian-Huan Chen
JCJiu Chen
Jiu Chen
FZFuquan Zhang
Fuquan Zhang

21 December 2024 in Journal of Affective Disorders
Verified
Journal Article
Closed access
QZQi Zhang
Qi Zhang
WZWenxuan Zhao
Wenxuan Zhao
YYYajun Yun
Yajun Yun
TMTing Ma
Ting Ma
HAHuimei An
Huimei An
FYFude Yang
Fude Yang

21 May 2024 in EBioMedicine
Verified
Journal Article
Open access
YLYundan Liao
Yundan Liao
YSYutao Sun
Yutao Sun
JGJing Guo
Jing Guo
ZKZhewei Kang
Zhewei Kang
YSYaoyao Sun
Yaoyao Sun
WYWeihua Yue
Weihua Yue
Understanding the impact of CYP2D6 metabolism on paroxetine, a widely used antidepressant, is essential for precision dosing. We conducted an 8-week, multi-center, single-drug, 2-week wash period prospective cohort study in 921 Chinese Han patients with depressive or anxiety disorders (ChiCTR2000038462). We performed CYP2D6 genotyping (single nucleotide variant and copy number variant) to derive the CYP2D6 activity score and evaluated paroxetine treatment outcomes including steady-state concentration, treatment efficacy, and adverse reaction. CYP2D6 metabolizer status was categorized into poor metabolizers (PMs), intermediate metabolizers (IMs), extensive metabolizers (EMs), and ultrarapid metabolizers (UMs). The influence of CYP2D6 metabolic phenotype on paroxetine treatment outcomes was examined using multiple regression analysis and cross-ethnic meta-analysis. The therapeutic reference range of paroxetine was estimated by receiver operating characteristic (ROC) analyses. After adjusting for demographic factors, the steady-state concentrations of paroxetine in PMs, IMs, and UMs were 2.50, 1.12, and 0.39 times that of EMs, with PM and UM effects being statistically significant (multiple linear regression, P = 0.03 and P = 0.04). Sex and ethnicity influenced the comparison between IMs and EMs. Moreover, poor efficacy of paroxetine was associated with UM, and a higher risk of developing adverse reactions was associated with lower CYP2D6 activity score. Lastly, cross-ethnic meta-analysis suggested dose adjustments for PMs, IMs, EMs, and UMs in the East Asian population to be 35%, 40%, 143%, and 241% of the manufacturer's recommended dose, and 62%, 68%, 131%, and 159% in the non-East Asian population. Our findings advocate for precision dosing based on the CYP2D6 metabolic phenotype, with sex and ethnicity being crucial considerations in this approach. National Natural Science Foundation of China; Academy of Medical Sciences Research Unit.

8 December 2020 in Frontiers in Psychiatry
Verified
Journal Article
Open access
XLXiaohong Liu
Xiaohong Liu
HZHongliang Zhou
Hongliang Zhou
CJChenguang Jiang
Chenguang Jiang
YXYanling Xue
Yanling Xue
ZZZhenhe Zhou
Zhenhe Zhou
JWJun Wang
Jun Wang
Alcohol dependence (AD) presents cognitive control deficits. Event-related potential (ERP) P300 reflects cognitive control-related processing. The aim of this study was to investigate whether cognitive control deficits are a trait biomarker or a state biomarker in AD. Participants included 30 AD patients and 30 healthy controls (HCs). All participants were measured with P300 evoked by a three-stimulus auditory oddball paradigm at a normal state (time 1, i.e., just after the last alcohol intake) and abstinence (time 2, i.e., just after a 4-week abstinence). The results showed that for P3a and P3b amplitude, the interaction effect for group × time point was significant, the simple effect for group at time 1 level and time 2 level was significant, and the simple effect for time point at AD group level was significant; however, the simple effect for time point at HC group level was not significant. Above results indicated that compared to HCs, AD patients present reductions of P3a/3b amplitude, and after 4-week alcohol abstinence, although P3a/3b amplitudes were improved, they were still lower than those of HCs. For P3a and P3b latencies, no significant differences were observed. These findings conclude that AD patients present cognitive control deficits that are reflected by P3a/3b and that cognitive control deficits in AD are trait- and state-dependent. The implication of these findings is helpful to understand the psychological and neural processes for AD, and these findings suggest that improving the cognitive control function may impact the treatment effect for AD.

1 November 2023 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
YSYifan Sun
Yifan Sun
ZHZixuan Huang
Zixuan Huang
XGXuezheng Gao
Xuezheng Gao
LCLimin Chen
Limin Chen
JWJun Wang
Jun Wang
HZHongliang Zhou
Hongliang Zhou
Purpose: Anhedonia, a core symptom of major depressive disorder (MDD), is explored in this study, focusing on the neural underpinnings through the examination of two event-related potential (ERP) components: feedback-related negativity (FRN) and stimulus-preceding negativity (SPN). Patients and Methods: This cross-sectional study was conducted in China from March 2022 to March 2023. It involved 35 MDD patients and 31 healthy controls (HC) participating in a modified 2-door task with simultaneous EEG recordings. Depression severity and anhedonia were assessed using the Hamilton Depression Scale (HAMD) and the Temporal Experience of Pleasure Scale (TEPS-CV), respectively. FRN and SPN metrics, along with correlations with each other and clinical assessments, were examined. Results: In comparison to the HC group, the MDD group exhibited significantly lower scores in TEPS-CV (t = 2.854, p = 0.006) and its subscales (t = − 3.596, p = 0.001 and t = 2.434, p = 0.018, respectively), along with consistently reduced amplitudes of FRN (F 1.64= 4.726, p = 0.033) and SPN (F 1.64= 4.195, p = 0.045) across all conditions. Limited correlations were observed between ERP metrics and clinical indicators, except for positive correlations between FRN amplitudes (loss minus win) and HAMD scores (r = 0.392, p = 0.020), and SPN amplitudes after losing (SPN-L) and TEPS-CV consumption subscale scores (r = 0.357, p = 0.035). Notably, while the HC group displayed no significant FRN-SPN correlations, the MDD group exhibited positive FRN-SPN correlations under distinct conditions (r = 0.376, p = 0.026 and r = 0.355, p = 0.037, respectively). Conclusion: Our data reveal subjective and objective anhedonia in both consumption and anticipation, suggesting a shared impairment in reward feedback processing and anticipatory neural mechanisms in individuals with MDD. These findings deepen our understanding of anhedonia’s neural foundations and may guide targeted interventions for this core symptom.

22 August 2024 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
MHMingru Hou
Mingru Hou
YWYuqing Wu
Yuqing Wu
JXJianhua Xue
Jianhua Xue
QCQiongni Chen
Qiongni Chen
YZYan Zhang
Yan Zhang
XLXianwen Li
Xianwen Li
Schizophrenia is a pervasive and severe mental disorder characterized by significant disability and high rates of recurrence. The persistently high rates of readmission after discharge present a serious challenge and source of stress in treating this population. Early identification of this risk is critical for implementing targeted interventions. The present study aimed to develop an easy-to-use predictive instrument for identifying the risk of readmission within 1-year post-discharge among schizophrenia patients in China. A prediction model, based on static factors, was developed using data from 247 schizophrenia inpatients admitted to the Mental Health Center in Wuxi, China, from July 1 to December 31, 2020. For internal validation, an additional 106 patients were included. Multivariate Cox regression was applied to identify independent predictors and to create a nomogram for predicting the likelihood of readmission within 1-year post-discharge. The model’s performance in terms of discrimination and calibration was evaluated using bootstrapping with 1000 resamples. Multivariate cox regression demonstrated that involuntary admission (adjusted hazard ratio [aHR] 4.35, 95% confidence interval [CI] 2.13–8.86), repeat admissions (aHR 3.49, 95% CI 2.08–5.85), the prescription of antipsychotic polypharmacy (aHR 2.16, 95% CI 1.34–3.48), and a course of disease ≥ 20 years (aHR 1.80, 95% CI 1.04–3.12) were independent predictors for the readmission of schizophrenia patients within 1-year post-discharge. The area under the curve (AUC) and concordance index (C-index) of the nomogram constructed from these four factors were 0.820 and 0.780 in the training set, and 0.846 and 0.796 for the validation set, respectively. Furthermore, the calibration curves of the nomogram for both the training and validation sets closely approximated the ideal diagonal line. Additionally, decision curve analyses (DCAs) demonstrated a significantly better net benefit with this model. A nomogram, developed using pre-discharge static factors, was designed to predict the likelihood of readmission within 1-year post-discharge for patients with schizophrenia. This tool may offer clinicians an accurate and effective way for the timely prediction and early management of psychiatric readmissions.